psyllium fibre (dietary supplement) + wheat bran (dietary supplement) + rice wheat (placebo)
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
22
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Colonic Diseases, Functional
Conditions
Colonic Diseases, Functional
Trial Timeline
Apr 1, 2005 → Apr 1, 2007
NCT ID
NCT00189033About psyllium fibre (dietary supplement) + wheat bran (dietary supplement) + rice wheat (placebo)
psyllium fibre (dietary supplement) + wheat bran (dietary supplement) + rice wheat (placebo) is a pre-clinical stage product being developed by Pfizer for Colonic Diseases, Functional. The current trial status is completed. This product is registered under clinical trial identifier NCT00189033. Target conditions include Colonic Diseases, Functional.
Hype Score Breakdown
Clinical
5
Activity
2
Company
9
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00189033 | Pre-clinical | Completed |
Competing Products
6 competing products in Colonic Diseases, Functional
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Enzastaurin HCl | Eli Lilly | Phase 2 | 52 |
| Entereg + Entereg + placebo | Merck | Phase 2 | 52 |
| Indium labeled IMP-205xm734 | Gilead Sciences | Phase 1 | 32 |
| Methylnaltrexone Bromide (MNTX) + Placebo | Pfizer | Approved | 84 |
| oxaliplatin | Sanofi | Approved | 84 |
| Oxaliplatin (SR96669) | Sanofi | Phase 3 | 76 |